US representative Katie Porter used her now-signature whiteboard as she questioned former Celgene CEO Mark Alles over the connection between the significant price hike for Revlimid, a common cancer drug, and his personal bonus.
The Democratic congresswoman for California presented her argument during a House oversight and reform committee hearing that centred on an 18-month investigation into pharmaceutical price gouging. The drug makers defended the price rises as the cost of doing research and development and talked about price-reduction programmes their companies offer
